ECE2022 Poster Presentations Pituitary and Neuroendocrinology (127 abstracts)
Efficacy of lanreotide 120 mg primary therapy on tumor shrinkage and ophthalmologic symptoms in acromegaly after one month
Hamza Benderradji 1 , Vernotte Elise 1 , Soto Ares Gustave 2 , Woillez Jean Philippe 3 , Perbet Romain 4 , Karnoub Mélodie-Anne 5 , Soudan Benoît 6 , Jannin Arnaud 7 , Richard Assaker 5 , Buée Luc 8 , Vincent Prevot 9 , Maurage Claude-Alain 4 , Pigny Pascal 6 , Vantyghem Marie-Christine 1 , Merlen Emilie 1 & Christine Cortet Rudelli 1
1Department of Endocrinology, Diabetology, and Metabolism, Lille University Hospital, Lille, France; 2Department of Radiology, Lille University Hospital, Lille, France; 3Department of Ophthalmology, Lille University Hospital, Lille, France; 4Department of Pathology, Lille University Hospital, Lille, France; 5Department of Neurosurgery, Lille University Hospital, Lille, France; 6Department of Biochemistry & Hormonology, Lille University Hospital, Lille, France; 7Department of Endocrinology, Diabetology, and Metabolism, Lille University Hospital, Nord, Lille, France; 8University of Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S1172, Lille, France; 9University of Lille, Inserm, CHU Lille, Lille Neuroscience & Cognition, UMR-S1172, Lille, France
Introduction: Few studies to date have attempted to evaluate the early efficacy of first-generation somatostatin analogs in somatotroph macroadenomas.
Objective: To investigate the short-term efficacy of primary therapy with lanreotide 120 mg on tumor shrinkage and ophthalmologic symptoms in newly diagnosed patients with acromegaly.
Design and patients: This single-center retrospective study included 21 patients who were newly diagnosed with acromegaly resulting from pituitary macroadenoma and were receiving a primary monthly treatment with lanreotide 120 mg. Clinical, hormonal, ophthalmologic and MRI scan evaluations were conducted after the first and the third months of treatment.
Results: Tumor volume reduction was more pronounced at one month [mean volume change -31.4 ± 19.5%, P<0.0001] than between the first and third month of treatment [mean volume reduction -20.6 ± 13.4%, P=0.0009]. The mean volume change between baseline and the third month was -46.4 ± 21.6, (P<0.0001). A significant volume reduction (≥ 25%) was observed in 61.9% of individuals (13/21) at the first month and in 82.3% (14/17) after three months of treatment. Among 14 individuals with optic chiasm compression and visual field defects, visual field normalization was observed in 3 cases (21.4%) and improvement in 7 cases (50%) at one month. The decrease in GH and IGF-1 serum values was significant at one month.
Conclusions: Primary treatment with lanreotide 120 mg in patients with somatotroph macroadenomas provides early significant tumor shrinkage with rapid improvement of visual symptoms at the end of the first month.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more